… In conclusion, Ronapreve, also known as REGEN-COV, is thought to be closely linked to
a reduction in the risk of hospitalization or the need for additional treatment, along with a …

… Dr Yancopoulos reported being an officer and director for Regeneron during the conduct
of the study and having multiple patents pending for REGEN-COV antibody, all assigned to …

… novel neutralizing monoclonal antibody cocktail REGEN-COV (… [2] REGEN-COV, recently
approved in Japan, is a combined … According to this report, REGEN-COV significantly reduced …

… IgG1 antibodies that targets the spike protein of SARS-CoV-2, … shown to reduce viral loads
of SARS-CoV-2 and improved viral … Each patient received a combination dose of 1200 mg of …

… Casirivimab/imdevimab (Ronapreve™; REGEN-COV™) is a co-packaged combination of
two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal antibodies (casirivimab …

… O’Brien and colleagues examined the efficacy of REGEN-COV administration as post-… of
SARS-CoV-2-infected individuals. REGEN-COV is a combination of two monoclonal antibodies, …

… REGEN-COV, the cocktail of monoclonal antibodies casirivimab and imdevimab, was given
Emergency Use Authorization (EUA) for the treatment of patients with mild-moderate COVID-…

… antibodies. These results suggest that the presence of heterodimers in co-formulated
REGEN-COV Ⓡ … Citation17 This combination of SEC and HIC has been demonstrated to enable …

… and imdevimab (REGEN-COV) monoclonal antibodies in combination with remdesivir resulted
… The REGEN-COV antibody cocktail may improve the outcome of SARS-CoV-2 infection in …

… [10] in hospitalized patients treated with REGEN-COV2 versus … REGEN-COV2 combination
antibody therapy showed … have not developed an antibody response to SARS-CoV-2 infection…